iCAD to Highlight ProFound AI™ Solution for Digital Breast Tomosynthesis at 2019 Society of Breast Imaging Annual Symposium
Company’s Latest, Deep-Learning,
Cancer Detection Software Solution Recently Launched in U.S.
Nashua, NH – (April 4,
2019) – iCAD, Inc. (NASDAQ:
ICAD), a global medical technology leader providing innovative cancer
detection and therapy solutions, today announced that it will present its
latest artificial intelligence software
solution for digital breast tomosynthesis (DBT), ProFound AI™, as well as its PowerLook
Density Assessment software, in the iCAD
exhibition booth #301 during the 2019 Society of Breast Imaging (SBI) Annual Symposium,
the largest breast imaging conference in the world. Hosted by the SBI and the American College of
Radiology, the conference will take place April 4-7, 2019, in Hollywood,
Florida.
ProFound
AI is a high-performance, deep-learning, cancer detection and workflow solution
for DBT. This transformational technology delivers critical benefits to
radiologists, their facilities and patients through the improvement of
cancer detection rates by an average of 8 percent and a reduction in the rate
of unnecessary patient recalls by an average of 7 percent. The technology is designed
to detect malignant soft-tissue densities and calcifications and provides radiologists
with the certainty of finding lesion and case scores. Since its U.S.
launch in December 2018, ProFound AI has been adopted by a significant number
of high-profile hospitals and imaging centers in all major geographic areas of
the country, demonstrating the strong need for such revolutionary technology.
“We look forward to engaging with breast imaging professionals at the
SBI Symposium to share our powerful ProFound AI solution that delivers vast improvements in clinical
performance and workflow,” said Stacey Stevens, President of ICAD. “We are pleased with the overwhelmingly positive feedback we
have received from
customers who have been early adopters of this technology.”
“Enhanced breast cancer detection remains a critical healthcare
initiative, as evidenced by the recently proposed regulations from the U.S.
Food and Drug Administration (FDA) requiring breast density reporting,”
continued Ms. Stevens. “The new proposed
regulations would enhance FDA’s ability to enforce mammography facilities’
compliance with breast density reporting standards. Importantly, iCAD’s PowerLook Density
Assessment software is designed to standardize the assessment of breast density in 2D
and 3D mammography. We believe this innovative technology could play an
important role in healthcare facilities’ ability to adhere to the new proposed
regulations from FDA.”
For
more information about iCAD and its solutions or to register for a meeting or
demonstration at SBI, please visit http://go.icadmed.com/SBI_2019.
About
iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical
technology leader providing innovative cancer detection and therapy solutions.
For more information, visit www.icadmed.com.
“Safe
Harbor” Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this News Release constitute
“forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements involve a number
of known and unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of the Company to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. Such factors include, but are not
limited to the Company’s ability to defend itself in litigation matters, to
achieve business and strategic objectives, the risks of uncertainty of patent
protection, the impact of supply and manufacturing constraints or difficulties,
uncertainty of future sales levels, protection of patents and other proprietary
rights, product market acceptance, possible technological obsolescence of
products, increased competition, litigation and/or government regulation,
changes in Medicare or other reimbursement policies, risks relating to our
existing and future debt obligations, competitive factors, the effects of a
decline in the economy or markets served by the Company; and other risks
detailed in the Company’s filings with the Securities and Exchange Commission.
The words “believe”, “demonstrate”, “intend”, “expect”, “would”, “could”,
“consider”, “project”, “estimate”, “will”, “continue”, “anticipate”, “likely”,
“seek”, and similar expressions identify forward-looking statements. Readers
are cautioned not to place undue reliance on those forward-looking statements,
which speak only as of the date the statement was made. The Company is under no
obligation to provide any updates to any information contained in this release.
For additional disclosure regarding these and other risks faced by iCAD, please
see the disclosure contained in our public filings with the Securities and
Exchange Commission, including the 10-K for the year ended December 31, 2018,
available on the Investors section of our website at http://www.icadmed.com and
on the SEC’s website at http://www.sec.gov.
Contact:
Investor Relations:
LifeSci Advisors, on behalf of iCAD, Inc.
Jeremy Feffer, (212) 915-2568